Read twice and referred to the Committee on Finance.

Original title: “S 3238: Conscience Protections for Medical Residents Act”

Referred to the Committee on Education and Workforce, and in addition to the Committees on Energy and Commerce, Oversight and Government Reform, and House Administration, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7686: Rural and Underserved Health Care Staffing Act”

Biologic copycats have had a limited impact on U.S. drug prices so far, but loosening regulatory restrictions could help accelerate their progress.

Original title: “New FDA guidance could elevate pharma’s biosimilar market”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 7685: Healthy Hair Act”

The biopharma business model is misaligned with rare diseases, and children are paying the price. Home » Rare Diseases » Rethinking How Rare Disease Treatments Get to Patients ... The biopharma business model is misaligned with rare diseases, and children are paying the price. Recent policy and market changes have sparked a dramatic shift in investment toward therapies with broad commercial demand — leaving hundreds of rare disease programs shelved, often despite promising clinical data. Matthews is a testament to how awareness can inspire progress. “When I joined forces with CureDuchenne, this was a relatively unknown disease,” he says. “But we’re at the point now where there are human clinical trials, and the symptoms of this disease are being checked.” “There have been huge leaps forward in genetic medicines to treat rare diseases, but the business model to support their advancement hasn’t evolved at the same pace,” shared Craig Martin, who founded the Orphan Therapeutics Accelerator (OTXL) to reimagine how rare disease treatments are financed and advanced. As a nonprofit, OTXL can incentivize companies to donate programs and negotiate deferred or reduced development costs with industry partners. In partnership with the American Society for Gene and Cell Therapy, OTXL is also building an AI-powered marketplace to surface shelved assets and match them with aligned funders, opening the door to family offices, impact investors, and others historically excluded from this space. Clay Matthews, the Super Bowl-winning linebacker for the Green Bay Packers, became a part of the rare disease community almost by chance. His first exposure to Duchenne, a rare muscle degeneration disease that affects boys, was for a CureDuchenne PSA that he lent his likeness to.

Original title: “Rethinking How Rare Disease Treatments Get to Patients - Future of Personal Health”

Learn about the salary and benefits of the Public Health Associate Program for Recent Graduates (PHA

Original title: “Associate Salary & Benefits”

Discover if you are eligible for CDC's PHAP program.

Original title: “Associate Eligibility & BEST FIT Model”

Understand the program's competencies and identify the associate learning objectives of PHAP.

Original title: “What Associates Learn and Do”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." This guidance document provides recommendations regarding non-clinical testing and clinical study design for medical devices with indications for use associated with weight loss to support premarket submissions. The guidance also includes discussion on how FDA considers the benefit-risk analysis to s

Original title: “Medical Devices With Indications Associated With Weight Loss-Premarket Considerations; Guidance for Industry and Food and Drug Administration Staff; Availability”

The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that

Original title: “Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; EYLEA HD (aflibercept)”

HHS herein publishes the panels of Schedule I and II drugs and biomarkers authorized for testing in federal workplace drug testing programs. The Department has made no revisions to the current drug testing panels for both urine and oral fluid and current required nomenclature for laboratory and Medical Review Officer Reports, effective July 7, 2025.

Original title: “Mandatory Guidelines for Federal Workplace Drug Testing Programs-Authorized Testing Panels”

Findings of research misconduct have been made against Chen- Yeh "George" Ke, Ph.D. (Respondent), former postdoctoral fellow, Department of Cell, Development and Regenerative Biology, Icahn School of Medicine at Mount Sinai. Dr. Ke engaged in research misconduct under 42 CFR part 93 in research included in one (1) draft manuscript and two (2) National Institutes of Health (NIH) Research Performance Progress Reports, specifically R01 DE022363-07 and R01 DE022363-08 submitted to the National Insti

Original title: “Findings of Research Misconduct”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Institutes of Health, National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection: 30-Day Comment Request; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (NCI)”

This notice describes the proposal to extend data collection under the Administration for Children and Families (ACF) Generic Program-Specific Performance Progress Report (PPR) (0970-0490). This overarching generic currently allows ACF program offices to collect performance and progress data from recipients and sub-recipients who receive funding from ACF under a grant or cooperative agreement. This generic mechanism provides the opportunity for ACF program offices to tailor requests for performa

Original title: “Submission for Office of Management and Budget Review; Generic Program-Specific Performance Progress Report”

Cloture on the motion to proceed to the measure not invoked in Senate by Yea-Nay Vote. 51 - 48. Record Vote Number: 644. (CR S8654-8655)

Original title: “S 3385: Lower Health Care Costs Act”

Cloture on the motion to proceed to the measure not invoked in Senate by Yea-Nay Vote. 51 - 48. Record Vote Number: 643. (CR S8654)

Original title: “S 3386: Health Care Freedom for Patients Act of 2025”

Held at the desk.

Original title: “S 355: FDA Modernization Act 3.0”

This report describes interim estimates of 2025-26 flu vaccine effectiveness in California during October 2025-January 2026.

Original title: “Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — California, October 2025–January 2026”

This report describes a measles outbreak in New Mexico in 2025.

Original title: “Measles Outbreak — New Mexico, 2025”

This report describes interim estimates of 2025-26 seasonal flu vaccine effectiveness.

Original title: “Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026”